J Gene Med January 2024 PMID 37985132

Pharmacogenomic evaluation of CYP2C19 alleles linking low clopidogrel response and the risk of acute coronary syndrome in Indians.

Keshavamurthy Ganapathy Bhat, Ratheesh Kumar Janardhana Pillai, Heemanshu Lodhi, Vivek Singh Guleria, Anil Kumar Abbot, Love Gupta, Garima Rastogi, Anuka Sharma, Zafar Mohammed, Varun Sharma

Full text PDF Download social card

Mentions

Peak: 1 in Nov 2023

across 2 sources since Nov 2023

Extended reach

611

potential audience

Total likes

Video views

Mentions per month

Nov 2023 – Dec 2024

Where it's discussed

X / Twitter2 posts
YouTube1 videos

AI synopsis

What people are saying

Overall, the discussions demonstrate strong agreement and high interest, with posts mentioning the potential to improve patient outcomes through genetic testing (e.g., 'Understanding these genetic influences is crucial') and discussing the study's implications for managing cardiovascular risks in Indians. The tone ranges from analytical to advocacy, indicating both a curiosity about the scientific details and a desire for real-world impact.

AgreementStrong agreement

Most discussions strongly support the findings, emphasizing their importance for personalized medicine in Indian populations.

InterestHigh interest

The posts reflect high interest, with commenters highlighting the relevance of genetic testing and treatment optimization.

EngagementModerate engagement

Some posts delve into the genetic mechanisms and clinical implications, showing meaningful engagement, though a few are more superficial.

ImpactHigh impact

The discussions recognize potential for significant change in clinical practices, advocating for tailored therapies based on genetic profiles.

Abstract in brief

Clopidogrel is commonly used to prevent heart-related issues in patients with coronary artery disease, but its effectiveness can vary due to genetic differences in the CYP2C19 gene, especially among South Asians who are at higher cardiac risk.
A study involving 1191 South Asian Indian individuals revealed a genetic link between CYP2C19 variants and acute coronary syndrome (ACS), highlighting that people with certain polymorphisms, like the *2 allele, are at increased risk, while the *17 allele may offer protective benefits.
Understanding these genetic influences is crucial for optimizing clopidogrel therapy and improving treatment outcomes for patients in this population.

Read the full abstract

All mentions

Pharmacogenomics of CYP2C19 and Clopidogrel Response in Indian CAD Patients

This study explores the genetic variations in CYP2C19 among Indian coronary artery disease patients and their impact on clopidogrel response, highlighting implications for personalized treatment strategies to reduce…

Varun Sharma · Dec 23, 2024 27 views

Varun Sharma

@sharmavarun840 · X

Mar 28, 2024 · 4 likes · 292 followers View post →